Modern concepts in the treatment of chronic lymphocytic leukemia

References

• Catovsky D, Richards S, Matutes E et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): a randomised controlled trial. Lancet 2007; 370(9583): 230–239.
   PubMed Web of Science ®Google Scholar
• Eichhorst BF, Busch R, Hopfinger G et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006; 107(3): 885–891.
   PubMed Web of Science ®Google Scholar
• Flinn IW, Neuberg DS, Greyer MR et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US intergroup trial E2997. J Gun Oncol 2007; 25(7): 793–798.
   Web of Science ®Google Scholar
• Keating MJ, O'Brien S, Albitar M et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23(18): 4079–4088.
   PubMed Web of Science ®Google Scholar
• Tam CS, O'Brien S, Wierda W et al. Long term results of the fludarabine, cyclophosphamide & rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008; 112(4): 975–980.
   PubMed Web of Science ®Google Scholar
• Wierda W, O'Brien S, Faderl S et al. A retrospective comparison ofthree sequential groups of patients with recurrent/refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer 2006; 106(2): 337–345.
   PubMed Web of Science ®Google Scholar
• Hallek M, Fingerle-Rowson G, Fink AM et al. Immunochemotherapy with Fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclopho-sphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 2008; 112: Abstract 325.
   Web of Science ®Google Scholar
• Robak T, Moiseev SI, Dmoszynska A et al. Rituximab, fludarabine, and cyclophosphamide (R-FC) prolongs progression free survival in relapsed or refractory chronic lymphocytic leukemia (CLL) compared with FC alone: final results from the International randomized phase III REACH trial. Blood (ASH Annual Meeting Abstracts) 2008; 112: Abstract 1.
   PubMedGoogle Scholar
• Boyiadzis M, Foon KA, Pavletic S. Hematopoietic stem cell transplantation for chronic lymphocytic leukemia: potential cure for an incurable disease. Expert Opin Biol Ther 2007; 7(12): 1789–1797.
   PubMed Web of Science ®Google Scholar
• CLL Trialists' Collaborative Group. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J Natl Cancer Inst 1999; 91(10): 861–868.
   PubMed Web of Science ®Google Scholar
• Dighiero G, Maloum K, Desablens B et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med 1998; 338(21): 1506–1514.
   PubMed Web of Science ®Google Scholar
• German CLL Study Group. Available from: http://dcllsg.web.me-d.uni-muenchen.de/en/c117/index.php (accessed 10 July 2008).
   Google Scholar
• Moreton P, Kennedy B, Lucas G et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005; 23(13): 2971–2979.
   PubMed Web of Science ®Google Scholar
• Wendtner CM, Ritgen M, Schweighofer CD et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission — experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 2004; 18(6): 1093–1101.
   PubMed Web of Science ®Google Scholar
• Montillo M, Tedeschi A, Miqueleiz S et al. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol 2006; 24(15): 2337–2342.
   PubMed Web of Science ®Google Scholar
• Lin TS, Donohue KA, Lucas MS et al. Therapy with subcutaneous (SC) alemtuzumab results in severe infectious toxicity in previously untreated CLL patients who achieve a complete response (CR) after fludarabine and rituximab (FR) induction therapy: interim safety analysis of the CALGB study 10101. Blood 2007; 110: Abstract 755.
   Web of Science ®Google Scholar
• Del Poeta G, Del Principe MI, Buccisano F et al. Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. Cancer 2008; 112(1): 119–128.
   PubMed Web of Science ®Google Scholar
• Bowen DA, Call TG, Jenkins GD et al. Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma 2007; 48(12): 2412–2417.
   PubMed Web of Science ®Google Scholar
• Dungarwalla M, Evans SO, Riley U et al. High dose methylpred-nisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy. Haematologica 2008; 93(3): 475–476.
   PubMed Web of Science ®Google Scholar
• Pettitt AR, Matutes E, Oscier D. Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects. Leukemia 2006; 20(8): 1441–1445.
   PubMed Web of Science ®Google Scholar
• Wierda WG, O'Brien S, Ferrajoli A et al. Salvage therapy with combined cyclophosphamide (C), fludarabine (F), alemtuzumab (A), and rituximab (R) (CFAR) for heavily pre-treated patients with CLL. Blood 2005; 106: Abstract 719.
   Web of Science ®Google Scholar
• Wierda, WG, O'Brien S, Ferrajoli A et al. Combined cyclopho-sphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active frontline regimen for high-risk patients with CLL. Blood 2007; 110: Abstract 628.
   Web of Science ®Google Scholar
• Elter T, Borchmann P, Schulz H et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 2005; 23(28): 7024–7031.
   PubMed Web of Science ®Google Scholar
• Bosch F, Ferrer A, Villamor N et al. Fludarabine, cyclopho-sphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication. Clin Cancer Res 2008; 14(1): 155–161.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Pocock C, Cohenz D et al. NCRI CLL201 Trial: a randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated CLL. Br J Haematol 2008; 141\(Suppl. 1): 119 ( Abstract 324).
   Google Scholar
• Knauf WU, Lissichkov T, Aldaoud A et al. Bendamustine versus chlorambucil in treatment-naive patients with B-cell chronic lymphocytic leukemia (B-CLL): results of an international phase III study. Blood 2007; 110: Abstract 2043.
   Web of Science ®Google Scholar
• Teeling JL, French RR, Cragg MS et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004; 104(6): 1793–1800.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepretre S, Pedersen LM et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008; 111(3): 1094–1100.
   PubMed Web of Science ®Google Scholar
• Osterborg A, Kipps T, Mayer J et al. Ofatumumab (HuMax-CD20), a novel CD20 monoclonal antibody, is an active treatment for patients with CLL refractory to both fludarabine and alemtuzumab or bulky fludarabine-refractory disease: results from the planned interim analysis of an international pivotal trial. Blood (ASH Annual Meeting Abstracts) 2008; 112: Abstract 328.
   Web of Science ®Google Scholar
• Available at: http://clinicaltrials.gov/ct2/show/NCT00410163 (accessed 10 July 2008).
   Google Scholar
• Byrd JC, O'Brien S, Flinn IW et al. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measure-ments in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res 2007; 13(15 Pt 1): 4448–4455.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Castro JE, Flinn IW et al. Lumiliximab in combination with FCR for the treatment of relapsed chronic lymphocytic leukemia (CLL): results from a phase I/II multicenter study. J Clin Oncol 2008; 25: Abstract 7003.
   Google Scholar
• Available at: http://clinicaltrials.gov/ct2/show/NCT00391066 (accessed 10 July 2008).
   Google Scholar
• Chanan-Khan A, Miller KC, Takeshita K et al. Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL). Blood 2005; 106(10): 3348–3352.
   PubMed Web of Science ®Google Scholar
• Kowal M, Podhorecka M, Gromek T et al. The assessment of antileucemic activity of thalidomide in combination with fludar-abine in patients with newly diagnosed and refractory or relapsed chronic lymphocytic leukemia. Haematologica 2008; 93\(Supp11): Abstract 1079.
   Google Scholar
• Chanan-Khan A, Miller KC, Musial L et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006; 24: 5343–5349.
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, Lee BN, Schlette El et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008; 111(11): 5291–5297.
   PubMed Web of Science ®Google Scholar
• Andritsos LA, Johnson AJ, Lozanski G et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol 2008; 26(15): 2519–2525.
   PubMed Web of Science ®Google Scholar
• Flinn IW, Byrd JC, Bartlett N et al. Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk Res 2005; 29(11): 1253–1257.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Lin TS, Dalton JT et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lym-phocytic leukemia. Blood 2007; 109(2): 399–404.
   PubMed Web of Science ®Google Scholar